Blueprint Medicines
(NASDAQ) BPMC
Blueprint Medicines Financials at a Glance
Market Cap
N/A
Revenue (TTM)
$562.12M
Net Income (TTM)
$155.73M
EPS (TTM)
N/A
P/E Ratio
N/A
Dividend
N/A
Beta (Volatility)
N/A
Dividend
N/A
Beta (Volatility)
N/A
Price
N/A
Volume
N/A
Open
N/A
Price
N/A
Volume
N/A
Open
N/A
Previous Close
N/A
Daily Range
N/A
52-Week Range
N/A
Dividend
N/A
Beta (Volatility)
N/A
Price
N/A
Volume
N/A
Open
N/A
Previous Close
N/A
Daily Range
N/A
52-Week Range
N/A
BPMC News
Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Blueprint Medicines
Industry
Biotechnology
Sector
Health CareEmployees
649
CEO
Kathryn Haviland, MBA
Website
www.blueprintmedicines.comHeadquarters
Cambridge, MA 02139, US
BPMC Financials
Key Financial Metrics (TTM)
Gross Margin
97%
Operating Margin
-28%
Net Income Margin
-17%
Return on Equity
-15%
Return on Capital
-9%
Return on Assets
-4%
Earnings Yield
N/A
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
N/A
Shares Outstanding
N/A
Volume
N/A
Short Interest
N/A
Avg. Volume
N/A
Financials (TTM)
Gross Profit
$488.66M
Operating Income
$212.04M
EBITDA
$19.23M
Operating Cash Flow
$192.59M
Capital Expenditure
$4.63M
Free Cash Flow
$197.22M
Cash & ST Invst.
$615.49M
Total Debt
$469.11M
Blueprint Medicines Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$149.41M
+55.5%
Gross Profit
$146.61M
+66.4%
Gross Margin
98.12%
N/A
Market Cap
N/A
N/A
Market Cap/Employee
N/A
N/A
Employees
682
N/A
Net Income
$496.00K
-99.4%
EBITDA
$41.09M
-137.6%
Quarterly Fundamentals
Net Cash
$453.49M
+807.6%
Accounts Receivable
$79.80M
+32.9%
Inventory
$12.95M
-58.1%
Long Term Debt
$65.22M
-87.2%
Short Term Debt
$57.53M
+35.6%
Return on Assets
-4.14%
N/A
Return on Invested Capital
-8.71%
N/A
Free Cash Flow
$56.31M
+45.1%
Operating Cash Flow
$54.48M
+46.3%